19:34 , Jul 13, 2018 |  BC Week In Review  |  Company News

Axovant gets rights to Benitec's gene therapy BB-301

Axovant Sciences Ltd. (NASDAQ:AXON) broadened its gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301. Axovant plans to start a placebo-controlled clinical trial next year of the gene...
04:00 , Jul 9, 2018 |  BC Extra  |  Company News

Axovant deepens gene therapy pipeline with Benitec deal

Axovant Sciences Ltd. (NASDAQ:AXON) broadened its gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301. Axovant plans to start a placebo-controlled clinical trial next year of the gene...
17:49 , Apr 6, 2018 |  BC Week In Review  |  Financial News

ALS newco QurAlis launches

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms. QurAlis is targeting three...
16:18 , Apr 5, 2018 |  BC Extra  |  Financial News

ALS newco QurAlis launches

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms. QurAlis is targeting three...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other molecule...
19:12 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest inhibiting TMX2 could help treat ALS caused by hexanucleotide repeat expansions in C9orf72. In a screen of a human acute myelogenous leukemia (AML) cell line and primary...
20:26 , Feb 23, 2018 |  BC Week In Review  |  Company News

Gilead picks Sangamo's ZFN gene editing for cell therapies

Sangamo Therapeutics Inc. (NASDAQ:SGMO) partnered with the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) to use Sangamo's zinc finger nuclease (ZFN) and adeno-associated virus (AAV) technology to develop next-generation autologous and allogeneic cell...
15:23 , Feb 23, 2018 |  BC Week In Review  |  Company News

Takeda, Wave in CNS nucleic acid deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases. Wave will receive an upfront payment of $170 million, including $110 million in...
23:07 , Feb 22, 2018 |  BC Extra  |  Company News

Sangamo, Gilead in cell therapy gene editing deal

Sangamo Therapeutics Inc. (NASDAQ:SGMO) gained $3.20 (14%) to $25.40 on Thursday after partnering with the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) to use Sangamo's zinc finger nuclease (ZFN) and adeno-associated virus (AAV)...
00:15 , Feb 21, 2018 |  BC Extra  |  Company News

Takeda, Wave in CNS nucleic acid deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases. Wave will receive an upfront payment of $170 million, including $110 million in...